Hengrui’s Docetaxel Use Ruled Not Infringing On Sanofi-Aventis’ Patent
This article was originally published in PharmAsia News
Executive Summary
Hengrui China's Patent Re-examination Board of the State Intellectual Property Office (SIPO) has ruled that the patent right of Aventis Pharma S.A. and Sanofi-Aventis for Docetaxel is invalid. If dissatisfied with the verdict, the plaintiffs can appeal to the Beijing Number One Intermediate People's Court within three months. Last September, Aventis Pharma and Sanofi-Aventis sued Jiangsu Hengrui in Beijing Municipal Higher People's Court for Docetaxel patent infringement, asking for patent fees of 45 million yuan ($6.4 million), financial loss compensation of 55 million yuan ($7.87 million), miscellaneous expenses of 200,000 yuan ($28,000) and full cost of the litigation. (Click here for more - Chinese language)
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.